WO2011044207A2 - Compositions présentant une forte concentration de sphingolipides polaires - Google Patents

Compositions présentant une forte concentration de sphingolipides polaires Download PDF

Info

Publication number
WO2011044207A2
WO2011044207A2 PCT/US2010/051591 US2010051591W WO2011044207A2 WO 2011044207 A2 WO2011044207 A2 WO 2011044207A2 US 2010051591 W US2010051591 W US 2010051591W WO 2011044207 A2 WO2011044207 A2 WO 2011044207A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
hexuronido
oil
inositolphosphoceramide
polar
Prior art date
Application number
PCT/US2010/051591
Other languages
English (en)
Other versions
WO2011044207A3 (fr
Inventor
Philippe Barbarat
Michel Philippe
Richard Martin
Original Assignee
L'oreal S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal S.A. filed Critical L'oreal S.A.
Publication of WO2011044207A2 publication Critical patent/WO2011044207A2/fr
Publication of WO2011044207A3 publication Critical patent/WO2011044207A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations

Definitions

  • compositions for topical application such as cosmetic or dermatologic compositions comprising a high concentration of polar sphingolipid(s).
  • Such compositions can be used in treating keratinous materials.
  • such compositions can be used for treating skin such as, for example, whitening or lightening skin, prevention or treatment of dry skin, and can be used in treating hair such as, for example, conditioning hair or hair protection.
  • Such compositions can also be used for nail and eyelash care.
  • Sphingolipids are a class of lipids derived from sphingosines
  • Ceramides are compounds in which a fatty acid chain is attached to sphingosine (which is the fundamental unit common to all sphingolipids) through an amide linkage.
  • Sphingomyelins have a phosphorylcholine or phosphoroethanolamine molecule linked to a ceramide.
  • Glycosphingolipids are ceramides with one or more sugar residues linked thereto.
  • Gangliosides have at least three sugars.
  • compositions containing sphingolipids of higher polarity which can treat conditions associated with, and/or improve the quality of, keratinous material such as skin, hair, nail or eyelash.
  • compositions for topical application comprising a high concentration of polar sphingolipid(s).
  • the present invention also relates to methods for lightening and/or skin whitening or for prevention or treatment of dry skin comprising topically applying to the skin of a mammal a composition comprising a high concentration of polar sphingolipid(s) in an amount sufficient to lighten and/or depigment the skin or to prevent and/or treat dry skin.
  • the present invention further relates to methods for conditioning hair or for hair protection comprising topically applying to the hair of a mammal a composition comprising a high concentration of polar sphingolipid(s) in an amount sufficient to condition and/or protect the hair.
  • the present invention also relates to methods of rejuvenating skin comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin in an amount sufficient to rejuvenate skin.
  • the present invention further relates to methods of improving skin tone comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin in an amount sufficient to improve skin pigmentation homogenization.
  • the present invention further relates to methods of treating melasma or vitiligo comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin in an amount sufficient to treat melasma or vitiligo.
  • the expression “at least one” means one or more and thus includes individual components as well as
  • Substituted means comprising at least one substituent.
  • substituents include atoms, such as oxygen atoms and nitrogen atoms, as well as functional groups, such as hydroxyl groups, ether groups, alkoxy groups, acyloxyalky groups, oxyalkylene groups, polyoxyalkylene groups, carboxylic acid groups, amine groups, acylamino groups, amide groups, halogen containing groups, ester groups, thiol groups, sulphonate groups, thiosulphate groups, siloxane groups, and polysiloxane groups.
  • the substituent(s) may be further substituted.
  • Volatile as used herein, means having a flash point of less than about 100°C.
  • Non-volatile as used herein, means having a flash point of greater than about 100°C.
  • the composition of the present invention may be in any form, either liquid or non-liquid (semi-solid, soft solid, solid, etc.).
  • it may be a paste, a solid, a gel, or a cream.
  • It may be an emulsion, such as an oil-in-water or water-in-oil emulsion, a multiple emulsion, such as an oil-in-water-in-oil emulsion or a water-in-oil-in-water emulsion, or a solid, rigid or supple gel.
  • the composition of the invention may, for example, comprise an external or continuous fatty phase.
  • the composition can also be a molded composition or cast as a stick or a dish.
  • hardness of the composition may also be considered.
  • the hardness of a composition may, for example, be expressed in gramforce (gf).
  • the composition of the present invention may, for example, have a hardness ranging from 20 gf to 2000 gf, such as from 20 gf to 900 gf, and further such as from 20 gf to 600 gf.
  • This hardness is measured in one of two ways.
  • a first test for hardness is according to a method of penetrating a probe into the composition and in particular using a texture analyzer (for example TA-XT2i from Rheo) equipped with an ebonite cylinder of height 25 mm and diameter 8 mm.
  • a texture analyzer for example TA-XT2i from Rheo
  • the hardness measurement is carried out at 20°C at the center of 5 samples of the composition.
  • the cylinder is introduced into each sample of composition at a pre-speed of 2 mm/s and then at a speed of 0.5 mm/s and finally at a post-speed of 2 mm/s, the total displacement being 1 mm.
  • the recorded hardness value is that of the maximum peak observed.
  • the measurement error is ⁇ 50gf.
  • the second test for hardness is the "cheese wire” method, which involves cutting an 8.1 mm or preferably 12.7 mm in diameter stick composition and measuring its hardness at 20°C using a DFGHS 2 tensile testing machine from Indelco-Chatillon Co. at a speed of 100 mm/minute.
  • the hardness value from this method is expressed in grams as the shear force required to cut a stick under the above conditions.
  • the hardness of compositions according to the present invention which may be in stick form may, for example, range from 30 gf to 300 gf, such as from 30 gf to 250 gf, for a sample of 8.1 mm in diameter stick, and further such as from 30 gf to 200 gf, and also further such as from 30 gf to 20 gf for a sample of 12.7 mm in diameter stick.
  • the hardness of the composition of the present invention may be such that the compositions are self-supporting and can easily disintegrate to form a satisfactory deposit on keratin materials.
  • this hardness may impart good impact strength to the inventive compositions, which may be molded or cast, for example, in stick or dish form.
  • stability is tested by placing the composition in a controlled environment chamber for 8 weeks at 25°C.
  • the physical condition of the sample is inspected as it is placed in the chamber.
  • the sample is then inspected again at 24 hours, 3 days, 1 week, 2 weeks, 4 weeks and 8 weeks.
  • the sample is examined for abnormalities in the composition such as phase separation if the composition is in the form of an emulsion, bending or leaning if the composition is in stick form, melting, or syneresis (or sweating).
  • the stability is further tested by repeating the 8-week test at 25°C, 37°C, 45°C and under freeze-thaw conditions.
  • a composition is considered to lack stability if in any of these tests an abnormality that impedes functioning of the composition is observed. The skilled artisan will readily recognize an abnormality that impedes functioning of a composition based on the intended application.
  • compositions and methods of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful.
  • compositions comprising a high concentration of polar sphingolipid(s) are provided.
  • Polar sphingolipids are amphiphilic compounds.
  • Polar sphingolipids include highly glycosylated inositolphosphoceramides, the structure of which is variable (depending upon, for example, the headgroup(s) of the polar sphingolipids).
  • polar sphingolipid structures are conserved, and polar sphingolipids from a given source share a common ceramide backbone.
  • polar sphingolipids comprise t18:1/h24:0 or t18:1/h22:0 ceramide which is linked to hexuronido-phosphoinositol.
  • hexose and/or hexosamine can initially be added, and then hexose and/or pentose sugars can be added to form polar sphingolipid(s).
  • the sugars may be substituted.
  • hexosamine may be acetylated.
  • particularly preferred sphingolipids of the present invention have the following structure:
  • each R group is independently selected from hydrogen and saturated or unsaturated, Ci to C 50 linear or branched, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl groups, optionally comprising one or more oxygen (for example, aldehyde, ketone, ester or ether group), sulphur and/or nitrogen atoms (for example, amide or cyano group), and/or bearing as a substituent one or more of the following atoms or groups of atoms: fluorine, hydroxyl, C3 to C 8 cycloalkyl, Ci to C 0 alkyl, C5 to do aryl, phenyl optionally substituted with 1 to 3 Ci to C3 alkyl groups, Ci to C 3 hydroxyalkyi or Ci to C 6 aminoalkyl, or an hexosamine or an hexose moiety optionally substituted with one or more hexose, pentose, or acy
  • X and Y are independently selected from saturated or unsaturated, C12 to C 3 o linear or branched, alkyl or arylalkyl groups, preferably a Ci 4 to C 2 6 group, and most preferably a C16 to C22 group, including all ranges and subranges therebetween.
  • N-acetylhexamino-hexuronido-inositolphosphoceramide, hexamino-hexuronido-inositolphosphoceramide, hexuronido- inositolphosphoceramide, hexo-hexamino-hexuronido- inositolphosphoceramide, (pento)hexo-hexamino-hexuronido- inositolphosphoceramide, (pento) 2 hexo-hexamino-hexuronido- inositolphosphoceramide, and (pento) 3 hexo-hexamino-hexuronido- inositolphosphoceramide are examples of preferred polar sphingolipids in accordance with the present invention.
  • polar sphingolipid(s) can be extracted from any tissue (for example, the flesh, cob, peel, shell, etc.) of a material from the plant kingdom, although extraction from seeds, nuts and leaves is preferred.
  • Preferred sources include, but are not limited to, almond, ginseng, soy, sunflower, sweet potato, rice, maize, peanut, cucumber, grape, olive, pineapple, banana, sesame, fig, onion, walnut, spinach, mango, tomato, hazelnut, papaya, strawberry, citrus, asparagus, hop, kiwi, almond, persimmon, peanut and/or avocado.
  • suitable extraction techniques can include those used for extraction of polar and/or fatty materials.
  • extraction can occur by isolating lipids on a column containing a fatty material or fatty chain and/or through extraction with a suitable solvent such as apolar solvent like hexane and/or water, possibly further containing other solvents such as alcohols (ethanol, propanol, butanol, etc.).
  • a suitable solvent such as apolar solvent like hexane and/or water, possibly further containing other solvents such as alcohols (ethanol, propanol, butanol, etc.
  • Such extraction if performed, is preferably performed at elevated temperatures (above room temperature), such as 50°C, 60°C, 70°C, etc.
  • sphingolipid(s) can be separated by ion-exchange.
  • Such procedures can be preceded by or followed by other known techniques such as, for example, subjecting the extracts to NaOH if lipids containing an ester functionality are being extracted. Further examples of techniques useful in such extraction may be found in Archives of Biochemistry and Biophysics 417 (2003) 219- 226 and in Plant Physiology and Biochemistry 43 (2005) 1031-1038, the contents of both of which are incorporated by reference in their entirety..
  • extraction can result in one or more purified polar sphingolipids (possibly containing minor amounts of impurities), an extract containing a typical amount of one or more polar sphingolipids, or an extract containing an increased concentration of one or more polar sphingolipids (extract enriched in polar sphingolipids).
  • compositions of the present invention comprise a high concentration of polar sphingolipid(s).
  • “high concentration” of polar sphingolipids it is meant that the composition contains the amounts indicated below of one or more purified polar sphingolipids, a larger amount of an extract enriched in polar sphingolipids (for example, an extract containing 50% polar sphingolipids would preferably be present in a composition in an amount ranging from 0.2% to 40% to yield a polar sphingolipid concentration of 0.1 % to 20%), or an even larger amount of a typical extract (for example, at least 1 %, preferably at least 5%, more preferably at least 10%, etc.).
  • such high concentration of polar sphingolipid(s) is an amount sufficient to affect a desired result such as, for example, lightening or skin whitening or conditioning hair, etc.
  • the amount of polar sphinglipid(s) present in the composition ranges from about 0.1 to less than 20% by weight, preferably from about 0.2 to about 15% by weight, preferably from about 0.3 to about 10% by weight, and preferably from about 1 .0 to about 8% by weight, based on the total weight of the composition, including all ranges and subranges within these ranges.
  • the composition may further comprise at least one additional active agent.
  • the composition may further comprise a skin lightening or whitening active agent or an agent for enhancing the skin lightening or whitening activity of the polar sphingolipid(s) such as, for example, hydroquinone and its derivatives, kojic acid and its derivatives, tyrosinase inhibitors, resorcinol and its derivatives, DHEA and its
  • a skin lightening or whitening active agent or an agent for enhancing the skin lightening or whitening activity of the polar sphingolipid(s) such as, for example, hydroquinone and its derivatives, kojic acid and its derivatives, tyrosinase inhibitors, resorcinol and its derivatives, DHEA and its
  • the composition may further comprise a hair conditioning agent such as, for example, a non-volatile silicone oil like polydimethylsiloxanes (PDMS), phenylated polyorganosiloxanes such as phenyltrimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenylmethyldimethyltrisiloxanes, diphenyldimethicones, phenyldimethicones and polymethylphenylsiloxanes, which may be fluorinated; polysiloxanes modified with fatty acids, with fatty alcohols or with polyoxyalkylenes, fluorosilicones and perfluorinated silicone oils, and mixtures thereof; a volatile silicone oil like linear or cyclic silicones, preferably with a viscosity at room temperature and at atmospheric pressure of less than 8 mm.sup.2/s (8 cSt), and in particular comprising
  • a hair conditioning agent such as, for example, a non-
  • a hydrocarbon-based oil an oil predominantly containing carbon and hydrogen atoms and especially alkyl or alkenyl chains, for instance alkanes or alkenes, but also an oil containing, in addition to hydrogen and carbon atoms, oxygen atoms in the form of an ether, ester, alcohol or carboxylic acid function
  • a hydrocarbon-based oil such as liquid paraffin or liquid petroleum jelly, mink oil, turtle oil, soybean oil,
  • triisostearate or diglyceryl triisostearate higher fatty alcohols containing at least 12 carbon atoms, such as stearyl alcohol or oleyl alcohol, linoleyl alcohol linolenyl alcohol, isostearyl alcohol or octyldodecanol; a wax such as waxes of natural origin (carnauba wax or candelilla wax) or of synthetic origin; linear or branched fatty alcohols comprising from 10 to 30 carbon atoms; and cationic conditioning polymers such as, for example, copolymers of vinyl monomers having cationic amine or quaternary ammonium
  • the additional active agent is preferably present in an amount ranging from about 0.1 to less than 20% by weight, more preferably from about 0.2 to about 1 5% by weight, more preferably from about 0.3 to about 10% by weight, more preferably from about 1 .0 to about 8% by weight, based on the total weight of the composition, including all ranges and subranges within these ranges.
  • composition of the invention can further optionally comprise any additive usually used in the field under consideration.
  • oils, water, pigments, solvents such as polyols, film forming agents, dispersants, antioxidants, sunscreens, preserving agents, fragrances, fillers, neutralizing agents, surfactants, and mixtures thereof can be added.
  • suitable additional components can be found in the other references which have been incorporated by reference in this application.
  • Still further examples of such additional ingredients may be found in the International Cosmetic Ingredient Dictionary and Handbook (9 th ed. 2002).
  • a person skilled in the art will take care to select the optional additional additives and/or the amount thereof such that the advantageous properties of the composition according to the invention are not, or are not substantially, adversely affected by the envisaged addition.
  • additives may be present in the composition in a proportion from 0% to 99% (such as from 0.01 % to 90%) relative to the total weight of the composition and further such as from 0.1 % to 50% (if present), including all ranges and subranges therebetween.
  • composition of the invention should be cosmetically or dermatologically acceptable, i.e., it should contain a nontoxic physiologically acceptable medium and should be able to be applied to the eyelashes of human beings.
  • compositions according to the present invention comprise at least one oil.
  • Suitable oils include volatile and/or non-volatile oils.
  • Such oils can be any acceptable oil including but not limited to silicone oils and/or hydrocarbon oils.
  • the composition of the present invention preferably comprise one or more volatile silicone oils.
  • volatile silicone oils include linear or cyclic silicone oils having a viscosity at room temperature less than or equal to 6cSt and having from 2 to 7 silicon atoms, these silicones being optionally substituted with alkyl or alkoxy groups of 1 to 10 carbon atoms.
  • Specific oils that may be used in the invention include octamethyltetrasiloxane,
  • decamethylcyclopentasiloxane dodecamethylcyclohexasiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane and their mixtures.
  • Other volatile oils which may be used include KF 96A of 6 cSt viscosity, a commercial product from Shin Etsu having a flash point of 94°C.
  • the volatile silicone oils have a flash point of at least 40°C.
  • Non-limiting examples of volatile silicone oils are listed in Table 1 below.
  • a volatile linear silicone oil may be employed in the present invention.
  • Suitable volatile linear silicone oils include those described in U.S. patent no. 6,338,839 and WO03/042221 , the contents of which are incorporated herein by reference.
  • the volatile linear silicone oil is decamethyltetrasiloxane.
  • the decamethyltetrasiloxane is further combined with another solvent that is more volatile than decamethyltetrasiloxane.
  • the composition of the present invention preferably comprises one or more non-silicone volatile oils and may be selected from volatile hydrocarbon oils, volatile esters and volatile ethers.
  • volatile non-silicone oils include, but are not limited to, volatile hydrocarbon oils having from 8 to 16 carbon atoms and their mixtures and in particular branched Ce to Ci 6 alkanes such as C 8 to C-I 6 isoalkanes (also known as isoparaffins), isododecane, isodecane, and for example, the oils sold under the trade names of Isopar or Permethyl.
  • the volatile non-silicone oils have a flash point of at least 40°C.
  • Non-limiting examples of volatile non-silicone volatile oils are given in Table 2 below.
  • the volatility of the solvents/oils can be determined using the evaporation speed as set forth in U.S. patent no. 6,338,839, the contents of which are incorporated by reference herein.
  • the composition comprises at least one non-volatile oil.
  • non-volatile oils that may be used in the present invention include, but are not limited to, polar oils such as: [0060] - hydrocarbon-based plant oils with a high triglyceride content consisting of fatty acid esters of glycerol, the fatty acids of which may have varied chain lengths, these chains possibly being linear or branched, and saturated or unsaturated; these oils are especially wheat germ oil, corn oil, sunflower oil, karite butter, castor oil, sweet almond oil, macadamia oil, apricot oil, soybean oil, rapeseed oil, cottonseed oil, alfalfa oil, poppy oil, pumpkin oil, sesame seed oil, marrow oil, avocado oil, hazelnut oil, grape seed oil, blackcurrant seed oil, evening primrose oil, millet oil, barley oil, quinoa oil, olive oil, rye oil, safflower
  • R 5 COOR 6 in which R 5 represents a linear or branched higher fatty acid residue containing from 1 to 40 carbon atoms, including from 7 to 19 carbon atoms, and R6 represents a branched hydrocarbon-based chain containing from 1 to 40 carbon atoms, including from 3 to 20 carbon atoms, with R 6 + R 7 > 10, such as, for example, Purcellin oil (cetostearyl octanoate), isononyl isononanoate, Ci 2 to C-I 5 alkyl benzoate, isopropyl myristate, 2-ethylhexyl palmitate, and octanoates, decanoates or ricinoleates of alcohols or of polyalcohols;
  • R 5 represents a linear or branched higher fatty acid residue containing from 1 to 40 carbon atoms, including from 7 to 19 carbon atoms
  • R6 represents a branched hydrocarbon-based chain containing from 1 to 40 carbon atoms, including from
  • hydroxylated esters for instance isostearyl lactate or diisostearyl malate; and pentaerythritol esters;
  • C 8 to C 2 6 fatty alcohols for instance oleyl alcohol, cetyl alcohol, stearyl alcohol, and cetearly alcohol; and [0064] - mixtures thereof.
  • non-volatile oils examples include, but are not limited to, non-polar oils such as branched and unbranched hydrocarbons and hydrocarbon waxes including polyolefins, in particular Vaseline (petrolatum), paraffin oil, squalane, squalene, hydrogenated polyisobutene, hydrogenated polydecene, polybutene, mineral oil, pentahydrosqualene, and mixtures thereof.
  • non-polar oils such as branched and unbranched hydrocarbons and hydrocarbon waxes including polyolefins, in particular Vaseline (petrolatum), paraffin oil, squalane, squalene, hydrogenated polyisobutene, hydrogenated polydecene, polybutene, mineral oil, pentahydrosqualene, and mixtures thereof.
  • the oil or oils may be present in an amount ranging from 0.1 to 90% by weight relative to the total weight of the composition, for example from 5 to 70%, and for example from 10 to 50%, including all ranges and subranges therebetween.
  • the compositions of the present invention further comprise water.
  • embodiment water is preferably present in an amount ranging from about 30 to about 90 %, preferably from about 40 to about 85%, and more preferably from about 50 to about 80 % relative to the total weight of the composition, including all ranges and subranges
  • compositions of the present invention are in the form of an emulsion.
  • Suitable emulsion forms include but are not limited to oil-in-water, water-in- oil, oil-in-water-in-oil, water-in-oil-in-water and nanoemulsions (emulsions whose oil globules are of very fine particle size, that is to say that they have a number-average size of less than about 100 nanometers (nm)).
  • Emulsions contain at least one oil phase and at least one aqueous phase.
  • emulsions contain surfactants or surfactant-like materials which provide stability to the emulsions and inhibit de-phasing of the emulsions.
  • methods for lightening and/or skin whitening comprising topically applying to the skin of a mammal, preferably a human, a composition comprising a high
  • concentration of polar sphingolipid(s) in an amount sufficient to lighten and/or depigment the skin are provided.
  • methods for preventing or treating dry skin comprising topically applying to the skin of a mammal, preferably a human, a composition comprising a high
  • concentration of polar sphingolipid(s) in an amount sufficient to prevent and/or treat dry skin are provided.
  • methods for conditioning hair comprising topically applying to the hair of a mammal, preferably a human, a composition comprising a high concentration of polar sphingolipid(s) in an amount sufficient to condition the hair are provided.
  • methods of rejuvenating skin comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin in an amount sufficient to rejuvenate skin are provided.
  • methods of improving skin tone comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin in an amount sufficient to improve skin pigmentation homogenization are provided.
  • methods of treating melasma or vitiligo comprising applying a composition comprising a high concentration of polar sphingolipid(s) to the skin of a mammal, preferably a human, in an amount sufficient to treat melasma or vitiligo are provided.
  • compositions of the present invention comprising a high concentration of polar sphingolipid(s) are applied topically to the desired area of the skin or hair of a person in need of the desired treatment in an amount sufficient to achieve the desired result.
  • the compositions may be applied to the desired area as needed, preferably once or twice daily, more preferably once daily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions destinées à une application topique, qui présentent une forte concentration de sphingolipides polaires.
PCT/US2010/051591 2009-10-06 2010-10-06 Compositions présentant une forte concentration de sphingolipides polaires WO2011044207A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24897309P 2009-10-06 2009-10-06
US61/248,973 2009-10-06

Publications (2)

Publication Number Publication Date
WO2011044207A2 true WO2011044207A2 (fr) 2011-04-14
WO2011044207A3 WO2011044207A3 (fr) 2011-10-13

Family

ID=43857362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051591 WO2011044207A2 (fr) 2009-10-06 2010-10-06 Compositions présentant une forte concentration de sphingolipides polaires

Country Status (1)

Country Link
WO (1) WO2011044207A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317840A (zh) * 2018-03-29 2019-10-11 赢创德固赛有限公司 制备鞘脂的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635536A (en) * 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US20070003509A1 (en) * 2005-06-30 2007-01-04 Mike Farwick Skin treatment composition
US20070053852A1 (en) * 2003-05-28 2007-03-08 Beutler Rolf D Lipidic protein-transfer systems and cosmetic/dermatological use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635536A (en) * 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US20070053852A1 (en) * 2003-05-28 2007-03-08 Beutler Rolf D Lipidic protein-transfer systems and cosmetic/dermatological use thereof
US20070003509A1 (en) * 2005-06-30 2007-01-04 Mike Farwick Skin treatment composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317840A (zh) * 2018-03-29 2019-10-11 赢创德固赛有限公司 制备鞘脂的方法
EP3546589A3 (fr) * 2018-03-29 2019-12-18 Evonik Operations GmbH Procédé de production de sphingolipides
US11155842B2 (en) 2018-03-29 2021-10-26 Evonik Operations Gmbh Process for preparing sphingolipids
CN110317840B (zh) * 2018-03-29 2024-03-08 赢创运营有限公司 制备鞘脂的方法
US11939612B2 (en) 2018-03-29 2024-03-26 Evonik Operations Gmbh Process for preparing sphingolipids

Also Published As

Publication number Publication date
WO2011044207A3 (fr) 2011-10-13

Similar Documents

Publication Publication Date Title
KR101925161B1 (ko) 쿠쿠르브산 화합물 및 소수성 이눌린을 포함하는 미용적 조성물
EP2694024B1 (fr) Compositions cosmétiques contenant de la 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone
ES2282318T3 (es) Composicion cosmetica que comprende heteropolimeros y una substancia solida y procedimiento de utilizacion de esta composicion.
BR112015020049B1 (pt) Composição na forma de uma emulsão óleo-em-água e processos cosméticos
JP7130867B2 (ja) 飽和脂肪アルコール、少なくとも１つの脂肪族鎖を有するアニオン性界面活性剤、ポリオール、及び少なくとも１種のシリコーン油を含む組成物
JPS61271205A (ja) 皮膚化粧料
WO2015028381A1 (fr) Composition d'hydratation pouvant être appliquée, pour mouiller la peau, sous la forme d'une émulsion huile-dans-eau ; procédé de soin d'hydratation
JP7308952B2 (ja) 多糖、ポリオール及び特定のエステルを含む組成物
US9095527B2 (en) Compositions containing acrylic thickener
WO2011044207A2 (fr) Compositions présentant une forte concentration de sphingolipides polaires
KR20130042918A (ko) 피부 유수분 밸런스 유지용 조성물 및 이를 포함하는 화장료 조성물
WO2020220277A1 (fr) Composition cosmétique sous forme d'émulsion huile-dans-eau
WO2014205813A1 (fr) Composition de prévention ou de réduction de la pigmentation de la peau et d'éclaircissement du teint de la peau, et utilisations associées
WO2021123352A1 (fr) Sérum à base de rétinol
US20230000729A1 (en) Lipsticks having natural oil, fatty alcohol wax and filler particles
JP6758877B2 (ja) Ｏ／ｗ型乳化組成物
WO2014205808A1 (fr) Composition topique de prévention ou de réduction de la pigmentation de la peau et/ou d'éclaircissement du teint de la peau et utilisation associée
JP7500355B2 (ja) Ｏ／ｗ型乳化組成物
EP4362898A1 (fr) Composition comprenant des aha et/ou des bha qui est stabilisée par une combinaison d'isosorbide monoalkylique ou dialkylique, d'éther de polyéthylène glycol-polypropylène glycol et de deux huiles végétales polyoxyéthylénées hydrogénées ou non hydrogénées
KR20240078295A (ko) 에스테르 및/또는 세라마이드를 포함하는 입술용 화장료 조성물
KR20240078582A (ko) 에스테르 및/또는 세라마이드를 포함하는 입술용 화장료 조성물
US20070105996A1 (en) Composition containing a hydroxyalkylurea and a polyolefin having a polar part
EP2512411B1 (fr) Composition à capacité d'hydratation améliorée
WO2023052587A1 (fr) Composition cosmétique comprenant au moins une huile polaire, un polyol et de l'acide ascorbique
JP2024076950A (ja) エステル及び／又はセラミドを含む唇用化粧料組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822584

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10822584

Country of ref document: EP

Kind code of ref document: A2